Indication intelligence, analysis and sector perception

Northwest Bio (NWBO) another 28.6 M share RDO priced at $0.35 and 50% warrant coverage for proceeds of $10 M

December 20, 2016 9:54am

NWBO closed at $0.49 and is trading DOWN -$0.08 at the open, so far; all I hear is the music for “Stay-in Alive” - SELL

NWBO will sell to the investors approximately 28.6 M shares of common stock at a purchase price of $.35 per share resulting in gross proceeds of $10 M.

The investors will also receive warrants to purchase up to approximately 14.3 M shares of common stock with an exercise price of $.35 per share and an exercise period of 5 years.

Chardan Capital Markets, LLC acted as the exclusive placement agent for the transaction. The placement is expected to close on or about December 23, 2016, subject to satisfaction of customary closing conditions.

A $0.14 discount on a $0.49 share price + 50% warrant coverage = SELL … bow, bow – let this dog out to do its “business”!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 43 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

13 hours 45 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.